Generative Chemistry Patents: Who Leads, Where the Gaps Are 2026
Generative Chemistry and Molecule Design Patents
Concentrated at the top. The five most active filers hold 74.1% of all 27 records in scope, with one company alone filing 9 — a tight cluster around synthetic accessibility and molecule generation, not a fragmented field. Filings held at zero through 2017 before building steadily; the field reached its recorded peak of 10 filings in 2025, though that figure and 2026's are still incomplete due to publication lag. The +500% rise from 2021 (1 filing) to 2024 (6 filings) is the clearest complete-year signal of momentum.
- 1INSILICO MEDICINE IP LTD9
- 2GOOD CHEMISTRY INC6
- 3QOMPLX INC2
- 4INSILICO MEDICINE AI LIMITED2
- 5THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES1
See the full generative chemistry and molecule design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions
Who are the leading patent filers in generative chemistry and molecule design?
The ranking covers 16 companies across the 27 records in scope, with the top filer alone accounting for 9 records. The top five filers combined hold 74.1% of all records, indicating a concentrated field where a small number of specialised applicants — mostly companies built around computational drug discovery — account for most of the claim activity. Beyond the top ranks, filing drops sharply, with fifth and tenth place each holding a single record, so the competitive core is narrow but the periphery is thin and contestable for new entrants.
How fast is patent filing growing in this field?
Filings rose from 1 in 2021 to 6 in 2024, a +500% increase over that three-year span, and the field reached a recorded peak of 10 filings in 2025. However, because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures are still incomplete and will rise as more applications publish. 2024 is the most recent year that can be treated as a complete data point for growth comparisons.
What technology areas dominate generative chemistry patent claims?
Computational chemistry (IPC class G16C) appears in 55.6% of the 27 records in scope, making it the single largest technology class, ahead of bioinformatics (G16B, 33.3%) and AI-model computing (G06N, 29.6%). Heterocyclic compound claims (C07D) and healthcare informatics (G16H) each appear in around a fifth of records, showing where generation methods intersect with specific chemical structures or clinical applications. Since a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be summed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Generative Chemistry and Molecule Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.